SGEN 228.74 (+0%)
US81181C1045BiotechnologyBiotechnology

Seagen (SGEN) Stock Highlights

228.74 | +0%
2024-12-21 00:22:02
Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagens therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The companys lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.

Statistics

Range Today
228.74 228.74
Volume Today 0
Range 1 Year
123.77 228.96
Volume 1 Year 356.98M
Range 3 Year
105.43 228.96
Volume 3 Year 867.13M
Range 10 Year
26.02 228.96
Volume 10 Year 2.71B

Highlights

Market Capitalization 43.15B (large)
Floating Shares 129.83M
Current Price 228.74
Price To Earnings -57.23
Price To Revenue 18.28
Price To Book 16.92
Earnings Per Share -4
Payout Ratio 0%

Performance

Latest 0%
1 Month +6.58%
3 Months +6.99%
6 Months +15.14%
1 Year +73.55%
3 Years +16.45%
5 Years +339.88%
10 Years +470.71%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.